Indaco Venture Partners
VC Fund
Milan, Italy
Indaco Venture Partners is an asset management company that invests in the technology, electronics, medtech, and materials sectors.
- Total investments:
- 47
- Last investment:
- Lead investor:
- 34%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Indaco Venture Partners invests in
BiotechnologyHealth CareLife ScienceMedicalTherapeutics
Stages Indaco Venture Partners invests in
Series ASeries BSeries CSeedFunding Round
Countries Indaco Venture Partners invests in
ItalyUnited KingdomSwitzerlandUnited StatesIsrael
Round sizes
Series A $3.3M–$31MSeries B $8.8M–$89MSeries C $16M–$110M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.3M–$31M
- Series B
- $8.8M–$89M
- Series C
- $16M–$110M
Investment Focus
Industry
- Biotechnology 14 (30%)
- Health Care 10 (21%)
- Life Science 6 (13%)
- Medical 5 (11%)
- Therapeutics 5 (11%)
Stage
- Series A 11 (23%)
- Series B 8 (17%)
- Series C 5 (11%)
- Seed 4 (9%)
- Funding Round 4 (9%)
Country
- Italy 18 (38%)
- United Kingdom 4 (9%)
- Switzerland 3 (6%)
- United States 3 (6%)
- Israel 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alvise Bonivento
Co-Founder, Investment Director & Board Member
|
Co-Founder, Investment Director & Board Member | Total investments: 2 | Find email | |
|
Antonella Beltrame
Partner
|
Partner | Total investments: 6 | Find email | |
Cosimo Calcagno
Investment Manager
|
Investment Manager | Total investments: 0 | Find email | |
Davide Turco
Managing Director and Founder
|
Managing Director and Founder | Total investments: 13 | Find email | |
Domenico Laudonia
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Newcleo
|
newcleo is the clean and safe nuclear technology company. Privately funded and headquartered in London, UK, newcleo was launched in 2021 to be a disruptor in the field of nuclear energy. Its mission is to generate safe, clean and inexhaustible energy for the world, through a radically innovative combination of existing, accessible technologies.newcleo is building the next generation system with the goals to: (1) eliminate the need for geological repositories by using a fast neutron flux avoiding production of long life radioactive elements; (2) develop an Accelerator Driven System (ADS), based on the intrinsically safe coupling of a particle accelerator and a sub-critical reactor; (3) accelerate the development of new fuel cycles, including thorium, that provide economic, clean, safe and inexhaustible energy from nuclei and the opportunity to burn the long-lived nuclear waste produced by the old generation of nuclear reactors.With visionary co-founders, newcleo brings together a team of engineers with deep knowledge of nuclear energy with younger recruits with a fresh mindset, working to design an innovative micro Lead Fast Reactor with significant commercial applications, for example in shipping. newcleo wants to be the first step toward the evolution of its industry to become fully respectful of people and the environment. To develop a new, sustainable, and completely safe way of generating nuclear energy that will lead humanity to zero emissions, and to the mitigation of global warming. | $88.6M / Series B / Feb 03, 2026 | |
Easy Rain
|
Easy Rain’s mission is to improve the safety of wheel vehicles, by contrasting a problem has not currently been addressed by any safety device, being the hydroplaning phenomenon. Hydroplaning is a phenomenon that causes loss of traction between a vehicle’s wheels and the roads surface due to the presence of a layer of water. Millions of accidentsevery year on wet roads. Also Autonomous driving technology has a big issue with wet roads.Easy Rain developed, tested, validated and patented a new driver assistance system specifically designed to contrast hydroplaning. The system prevents large amounts of water from touching the tire, thereby improving a vehicle’s performance and safety, by increasing the adherence of the tire on wet surfaces. | $3M / Venture - Series Unknown / Jul 08, 2025 | |
Iama Therapeutics
|
At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need. | $17.1M / Venture - Series Unknown / Apr 16, 2025 | |
CamGraPhIC
|
CamGraPhIC designs, develops, and manufactures next-generation photonic circuits for telecoms and datacoms. | $27M / Series A / Mar 24, 2025 | |
Valo Therapeutics
|
Valo Therapeutics is an immunotherapy company that is developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The Valo Tx platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenovirusesinto targeted tissue specific cancer vaccines without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiENV, among other neoantigen strategies, in collaboration with Professor Cerullo. PeptiENV is expected to improve the therapeutic response to enveloped oncolytic viruses in the treatment of multiple forms of cancer. | $20.6M / Venture - Series Unknown / Mar 10, 2025 | |
Newronika
|
Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies. | $14.2M / Series B / Feb 13, 2025 | |
|
Easy Rain
|
Easy Rain’s mission is to improve the safety of wheel vehicles, by contrasting a problem has not currently been addressed by any safety device, being the hydroplaning phenomenon. Hydroplaning is a phenomenon that causes loss of traction between a vehicle’s wheels and the roads surface due to the presence of a layer of water. Millions of accidentsevery year on wet roads. Also Autonomous driving technology has a big issue with wet roads.Easy Rain developed, tested, validated and patented a new driver assistance system specifically designed to contrast hydroplaning. The system prevents large amounts of water from touching the tire, thereby improving a vehicle’s performance and safety, by increasing the adherence of the tire on wet surfaces. | $2.6M / Jan 23, 2025 | |
|
Easy Rain
|
Easy Rain’s mission is to improve the safety of wheel vehicles, by contrasting a problem has not currently been addressed by any safety device, being the hydroplaning phenomenon. Hydroplaning is a phenomenon that causes loss of traction between a vehicle’s wheels and the roads surface due to the presence of a layer of water. Millions of accidentsevery year on wet roads. Also Autonomous driving technology has a big issue with wet roads.Easy Rain developed, tested, validated and patented a new driver assistance system specifically designed to contrast hydroplaning. The system prevents large amounts of water from touching the tire, thereby improving a vehicle’s performance and safety, by increasing the adherence of the tire on wet surfaces. | $2.6M / Jan 23, 2025 | |
TES Pharma
|
TES Pharma is a research-based biopharmaceutical company focusses on delivering first in class preclinical candidates that unlock the potential of novel therapeutic targets and mechanisms. | $5.2M / Series A / Dec 19, 2024 | |
|
TES Pharma
|
TES Pharma is a research-based biopharmaceutical company focusses on delivering first in class preclinical candidates that unlock the potential of novel therapeutic targets and mechanisms. | $5.2M / Series A / Dec 19, 2024 | |
| See all 47 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Life Science Investors
6,823 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does Indaco Venture Partners invest in?
Indaco Venture Partners invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 47 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Indaco Venture Partners's check size?
Indaco Venture Partners typically joins rounds of $3.3M–$31M at Series A, $8.8M–$89M at Series B and $16M–$110M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Indaco Venture Partners participates in.
How do I contact Indaco Venture Partners?
Public channels for Indaco Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Indaco Venture Partners?
The team at Indaco Venture Partners includes Alvise Bonivento (Co-Founder, Investment Director & Board Member), Antonella Beltrame (Partner) and Cosimo Calcagno (Investment Manager), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
